摘要
目的观察分析氟达拉滨联合中剂量阿糖胞苷在急性髓系白血病巩固治疗中的应用疗效。方法我院2017年1月至2018年1月34例急性髓系白血病患者均给予氟达拉滨治疗,在此基础上按照阿糖胞苷给药剂量不同将所有患者随机分为中剂量组(17例)与大剂量组(17例),比较两组患者预后情况。结果中剂量组患者近期治疗总有效率明显优于大剂量组(88.2%VS65.7%),中剂量组患者不良反应发生率明显低于大剂量组(17.6%VS35.3%),两组患者各项数据差异具有统计学意义(P<0.O5)。结论急性髓系白血病患者给予氟达拉滨联合中剂量阿糖胞苷安全性高,疗效好。
Objective to observe and analyze effect of fludarabine combined with medium dose cytarabine in consolidation therapy of acute myeloid leukemia. Methods choose 34 cases acute myeloid leukemia patients in our hospital from January 2017 to January 2018 as experimental objects, divide them into middle dose group（17 cases） and large dose group（17 cases） randomly. 17 cases in large dose group were treated with large dose arabine combined with fludarabine, 17 cases in middle dose group with combination of fludarabine. Compare prognosis situation of two groups. Results recent total effective rate of middle dose group was significantly better than large dose group（88.2%VS65.7%）. Adverse reactions incidence of middle dose group was significantly lower than large dose group（17.6%VS35.3%）, data differences showed statistical significance between two groups,（P〈0.O5）. Conclusion fludarabine combined with medium dose cytarabine has high safety and good effect in consolidation therapy of acute myeloid leukemia.
作者
杜宗彦
DU Zong-yan(Dezhou City Hospital,Dezhou,Shandong,25300)
出处
《智慧健康》
2018年第12期98-99,共2页
Smart Healthcare
关键词
氟达拉滨
中剂量阿糖胞苷
急性髓系白血病
巩固治疗
Fludarabine
Medium dose cytarabine
Acute myeloid leukemiai Consolidation therapy
